Delivery & enabling technology
Explore a paper’s conversation or start a broader discussion below.
Liposomal delivery: when usable yield changes the investment case
Vyxeos provides the clinical anchor; a separate yield and cash-cost model tests whether a manufacturing improvement deserves investment.
The Invisible Factory Behind Every Breakthrough
A discovery becomes a medicine through thousands of repeatable decisions. Step inside the less visible world that turns a promising result into reliable supply.
A Human Organ Small Enough for a Chip
Living cells and carefully engineered channels offer a new window into human biology. The important question is which part of an organ a tiny model can faithfully represent.
A device investment committee needs the sham-control question
SYMPLICITY HTN-3 frames a hypothetical device trial budget, site plan and milestone gate.
What is a second manufacturing source actually worth?
Genzyme’s remediation history anchors a hypothetical outage-exposure and backup-capacity decision.
Data integrity is an acquisition workstream with its own clock
A historical gene-therapy data issue informs a hypothetical audit, remediation and transaction-delay model.
The CAR-T slot is a promise across two organizations
Kymriah and current cell-therapy commercialization frame manufacturing reliability, release timing and patient readiness.
Casgevy’s delivery lesson: patient benefit still needs a treatment slot
Original gene-editing evidence and 2026 launch revenue inform a hypothetical treatment-center capacity model.
From evidence to execution: an operating model for lean biotech teams
Coordinate clinical, regulatory and manufacturing decisions with clear ownership, acceptance criteria and measurable handoffs.
Microneedle vaccine patches: bridge immunogenicity to real-world usability
A small Phase I study provides a useful early signal and a clear boundary around what remains to be demonstrated.
Antibody–drug conjugates: delivery performance includes the safety burden
A randomized breast-cancer trial shows why efficacy and adverse-event context belong in the same product discussion.
RNA delivery and endpoint discipline: lessons from the ORION trials
Two randomized trials illustrate how to communicate a strong biomarker result without extending it beyond the measured outcome.
qHTS: automate the evidence, then measure the workflow
The NIH titration-screening example shows why a richer experiment can matter more than a throughput ranking.
Cold-chain evidence: the Pfizer vaccine illustrates a stability milestone
A historical storage change shows why a process convenience needs product-specific supporting data.
Annovera: a reusable format still needs efficacy and usability evidence
The 2018 contraceptive-ring program separates duration, pregnancy outcomes, and real-world handling.
Afrezza: inhaled delivery brings a pulmonary workflow
The original 2014 authorization illustrates how a delivery route adds screening and monitoring dependencies.
Discussion
Share evidence, ask a question, or offer a professional perspective. Community guidelines
Loading discussion…